Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 2018

View Archived Issues

Mitsubishi Tanabe presents milestones of fourth quarter of fiscal 2017

First patient dosed in phase II study of eFT-508 plus avelumab in colorectal cancer

RXi Pharmaceuticals enters research agreement with Iovance Biotherapeutics

Porcine optic nerve injury model created to study nerve regeneration

Novel p95HER2-TCB demonstrates efficacy and safety in preclinical models of breast cancer

Merck & Co. patents KDM5B inhibitors

Shanghai Pharmaceuticals Holding discloses IDO-1 inhibitors

Bayer and collaborators identify DHOdehase inhibitors

BioIncept's PIF-1 designated as orphan drug by FDA for prevention of graft-versus-host-disease

FDA awards ImmunoGen's IMGN-779 orphan drug designation for AML

FDA approves Gilenya to treat MS in pediatric patients

Ono Pharmaceutical reflects on achievements of fourth quarter of fiscal 2017

Sanofi announces success of initial tender offer for acquisition of Ablynx

Inovio studies VGX-3100 in new phase II trial for HPV-16 or -18 related anal or peri-anal HSIL

Phase II trial in China studies SHR-1210 for advanced biliary tract cancer

Tumor growth inhibition seen with Jubilant Biosys LSD1/HDAC inhibitors

Medigene and bluebird bio expand TCR alliance

Human evaluation of CAR T cells targeting ROR1 underway

Beam Therapeutics launches with focus on creating precision genetic medicines through base editing

Poseida Therapeutics presents clinical data on P-BCMA-101 for relapsed/refractory multiple myeloma

Polaris collaborates with MD Anderson Cancer Center to utilize immunotherapy platform

CS-1003 begins phase I trial in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...